Shengyu Bio
圣域生物
Shengyu Bio
Biotech/Healthcare
Shengyu Biotech focuses on DNA damage repair, with a pipeline targeting next-generation synthetic lethality mechanisms. The company is developing original oncology drugs with proprietary intellectual property.
Latest round: Series A (2025)
Source: ChinaBulls — chinabulls.com
Last updated 2025-12-01
Funding history
Request access to view this section.
Investors
Request access to view this section.
HQ & website
Request access to view this section.
Tags
Request access to view this section.